
Your Feed
Serum Biomarkers and Progression Risk in Smoldering Myeloma | Theresia Akhalghi, MD | ASH 2023
Pathogenic Germline Variants in Cancer Predisposition Genes | Santiago Thibaud, MD | ASH 2023
Key Updates in MDS: Commands and Imerge Trials, Venetoclax Insights | David Swoboda, MD | ASH 2023
Investigating Prognostic Significance of Malnutrition in AML | Samuel Yates, MD, MS | ASH 2023
Unscheduled Interactions in Outpatient Bispecific Therapy for RRMM | Anna Howard, RN | ASH 2023
Benefits of Early MGUS Screening: iStopMM Study Results | Sæmundur Rögnvaldsson, MD, PhD | ASH 2023
Telehealth Program for Older Patients & Decision Preferences in AML | Jane Liesveld, MD | ASH 2023
GPRC5D Directed CAR T-Cell Therapy | University of Alabama | Susan Bal, MD | ASH 2023






